Ligand id: 8922

Name: risankizumab

No information available.
Summary of Clinical Use
Results from the first-in-human proof-of-concept trial in patients with psoriasis were reported by Krueger et al. in 2015 [7]. Phase 3 trial results in psoriasis patients were published in 2018 [6]. FDA and EMA approvals were granted in 2019 and it is also approved in Japan and Canada. Risankizumab therapy is indicated for patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy (Japan's authorisation additionally includes treatment of generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis). Investigations are ongoing in other autoinflammatory conditions. Click here to link to ClinicalTrials.gov's full list of risankizumab trials.
Mechanism Of Action and Pharmacodynamic Effects
The IL-23/IL-17 axis plays an important role in the development of chronic inflammation [5], with potential genetic links between the IL-23 receptor (IL-23R) or its ligand identified in inflammatory diseases such as psoriasis, inflammatory bowel disease [8], and graft-versus-host disease [2-4,10]. Signaling through the IL-23R induces Janus kinase 2 (JAK2) and tyrosine kinase 2 (TYK2) phosphorylation and leads to increased levels of the inflammatory cytokines IL-17 and IL-23. Risankizumab binds to the p19 subunit of IL-23, IL-23A, preventing receptor activation and thereby disrupting the IL-23/IL-17 axis.